A patent may cover technology that delivers substantial commercial benefits, yet the price it commands in a licensing negotiation can be far lower—or occasionally higher—than its economic value suggests. According to a recent IPWatchdog panel discussion, the gap arises because legal risk, enforcement costs, negotiating leverage, and each party's business objectives all influence what a patent is really worth in practice.
The panel, drawn from litigation and economic consulting, stressed that valuation starts with the invention's commercial contribution: whether it cuts production costs, boosts profitability, or drives demand. But that is only the beginning. Uncertainty about infringement or validity—through Section 101 challenges, PTAB proceedings, or prior-art attacks—can reshape the negotiating landscape even when the technology itself is unchanged. For individual inventors and smaller patent owners, these constraints are especially consequential.
Two recurring damages issues also complicate the picture: comparable licenses and apportionment. A royalty rate from another agreement is meaningful only when differences in products, markets, timing, portfolio scope, and contractual terms are understood. Likewise, valuing a patented feature in a complex, multicomponent product requires careful attention to its actual contribution. The panel also noted that agreements bundling trade secrets and know-how, or involving SEP/FRAND commitments, demand clear documentation of economic rationale.
The practical takeaway is to align legal strategy, economic analysis, and commercial objectives early. Damages experts can help identify useful discovery and test assumptions before an expert report is needed, and counsel can use contingent payments or other provisions to allocate risk rather than treating the royalty figure as the whole negotiation. Revisiting the client's goals throughout the process helps ensure the chosen path still serves the business.